<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00907868</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000636007</org_study_id>
    <secondary_id>RECF0911</secondary_id>
    <secondary_id>VA-2008/25</secondary_id>
    <secondary_id>2008-A00494-51</secondary_id>
    <nct_id>NCT00907868</nct_id>
  </id_info>
  <brief_title>Breast-Conserving Surgery and Whole-Breast Radiation Therapy With or Without Additional Radiation Therapy to the Tumor in Treating Women With Ductal Carcinoma in Situ (BONBIS)</brief_title>
  <acronym>BONBIS</acronym>
  <official_title>A Multicentric Phase III Trial Evaluating the Impact of a Radiation Boost (16Gy) After Breast Conserving Surgery and a Whole Breast Irradiation (50Gy) for DCIS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut du Cancer de Montpellier - Val d'Aurelle</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut du Cancer de Montpellier - Val d'Aurelle</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation&#xD;
      therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known&#xD;
      whether whole-breast radiation therapy is more effective when given with or without&#xD;
      additional radiation therapy to the tumor in treating patients with ductal carcinoma in situ.&#xD;
&#xD;
      PURPOSE: This randomized phase III trial is studying breast-conserving surgery followed by&#xD;
      whole-breast radiation therapy to see how well it works when given with or without additional&#xD;
      radiation therapy to the tumor in treating women with ductal carcinoma in situ.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Estimate and compare local recurrence-free survival of women with ductal breast&#xD;
           carcinoma in situ (DCIS) treated with breast-conserving surgery followed by whole breast&#xD;
           irradiation with vs without a radiation tumor bed boost.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare relapse-free survival between the two arms.&#xD;
&#xD;
        -  Compare overall survival.&#xD;
&#xD;
        -  Compare acute and late toxicities.&#xD;
&#xD;
        -  Compare cosmetic results and quality of life.&#xD;
&#xD;
        -  Identify patients at risk for late toxicities using a biological test.&#xD;
&#xD;
      Tertiary&#xD;
&#xD;
        -  Store blood samples at the CEPH (French Center of the Human Polymorphism Center) for&#xD;
           polymorphism analyses.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. All patients undergo breast-conserving surgery (after a&#xD;
      single intervention or second excision) with a margin ≥ 1 mm. A superficial or deep margin is&#xD;
      acceptable if the surgery has left the skin tissue or the fascia pectoral muscle,&#xD;
      respectively. Twelve weeks later, patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I: Patients undergo whole breast irradiation (WBI) once daily, 5 days a week for 5&#xD;
           weeks.&#xD;
&#xD;
        -  Arm II: Patients undergo WBI as in arm I. Patients also undergo a radiation tumor bed&#xD;
           boost once daily for 8 fractions (weekdays only) over 2 weeks.&#xD;
&#xD;
      Quality of life will be assessed.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 6 months for 5 years and&#xD;
      then annually for 10 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2008</start_date>
  <completion_date type="Anticipated">October 2029</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to recurrence</measure>
    <time_frame>up to 15 years of follow up</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2004</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients undergo whole breast irradiation (WBI) once daily for 5 weeks (weekdays only).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergo WBI as in arm I and a radiation tumor bed boost once daily for 8 days (weekdays only).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>partial breast irradiation</intervention_name>
    <description>Patients undergo radiation tumor bed boost</description>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>whole breast irradiation</intervention_name>
    <description>Patients undergo whole breast irradiation</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed ductal carcinoma in situ of the breast&#xD;
&#xD;
               -  No invasive component&#xD;
&#xD;
               -  No clinically palpable lymph node or presence of tumor cells in the sentinel&#xD;
                  lymph node (if done)&#xD;
&#xD;
               -  No local recurrence of a primary breast cancer&#xD;
&#xD;
               -  No multicentric or multifocal tumors not suitable for conservative surgery R0&#xD;
                  with a margin ≥ 1 mm&#xD;
&#xD;
          -  Has undergone bilateral mammography within 6 months before randomization&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 5 years&#xD;
&#xD;
          -  Not pregnant&#xD;
&#xD;
          -  Available for long-term follow up&#xD;
&#xD;
          -  No history of in situ carcinoma in the contralateral breast&#xD;
&#xD;
          -  No history of another cancer except for basal cell carcinoma of the skin or carcinoma&#xD;
             in situ of the cervix&#xD;
&#xD;
          -  No uncontrolled cardiac, renal, or pulmonary disease&#xD;
&#xD;
          -  No uncontrolled systemic disease (e.g., lupus erythematosus or scleroderma)&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  Affiliated with the social health system&#xD;
&#xD;
          -  No psychological, familial, sociological, or geographical situations that preclude&#xD;
             compliance with study treatment and follow up&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent participation in another therapeutic trial (participation in&#xD;
             epidemiologic studies is allowed)&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Azria, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut du Cancer de Montpellier - Val d'Aurelle</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.e-cancer.fr/Professionnels-de-sante/Le-registre-des-essais-cliniques/Le-registre-des-essais-cliniques/Etudes-cliniques/BONBIS-Essai-de-phase-3-randomise-evaluant-l-efficacite-d-un-complement-de-radiotherapie-apres-traitement-conservateur-chez-des-patientes-ayant-un-cancer-du-sein.-essai-clos-aux-inclusions</url>
    <description>Clinical trial summary from the National Cancer Institute's PDQ® database</description>
  </link>
  <reference>
    <citation>Azria D, Gourgou S, Sozzi WJ, Zouhair A, Mirimanoff RO, Kramar A, Lemanski C, Dubois JB, Romieu G, Pelegrin A, Ozsahin M. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer. 2004 Oct 4;91(7):1251-60.</citation>
    <PMID>15328527</PMID>
  </reference>
  <reference>
    <citation>Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad WJ, Oei SB, Wárlám-Rodenhuis CC, Pierart M, Collette L. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol. 2007 Aug 1;25(22):3259-65. Epub 2007 Jun 18.</citation>
    <PMID>17577015</PMID>
  </reference>
  <reference>
    <citation>EORTC Breast Cancer Cooperative Group; EORTC Radiotherapy Group, Bijker N, Meijnen P, Peterse JL, Bogaerts J, Van Hoorebeeck I, Julien JP, Gennaro M, Rouanet P, Avril A, Fentiman IS, Bartelink H, Rutgers EJ. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853--a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol. 2006 Jul 20;24(21):3381-7. Epub 2006 Jun 26.</citation>
    <PMID>16801628</PMID>
  </reference>
  <reference>
    <citation>Bijker N, Peterse JL, Duchateau L, Julien JP, Fentiman IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver MJ. Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol. 2001 Apr 15;19(8):2263-71.</citation>
    <PMID>11304780</PMID>
  </reference>
  <reference>
    <citation>Cutuli B, Cohen-Solal-le Nir C, de Lafontan B, Mignotte H, Fichet V, Fay R, Servent V, Giard S, Charra-Brunaud C, Lemanski C, Auvray H, Jacquot S, Charpentier JC. Breast-conserving therapy for ductal carcinoma in situ of the breast: the French Cancer Centers' experience. Int J Radiat Oncol Biol Phys. 2002 Jul 15;53(4):868-79.</citation>
    <PMID>12095552</PMID>
  </reference>
  <reference>
    <citation>Cutuli B, Fourquet A, Luporsi E, Arnould L, Caron Y, Cremoux Pd, Dilhuydy JM, Fondrinier E, Fourme E, Giard-Lefevre S, Blanc-Onfroy ML, Lemanski C, Mauriac L, Sigal-Zafrani B, Tardivon A, This P, Tunon de Lara C, Kirova Y, Fabre N; Federation of French Cancer Centres (FNCLCC), et le groupe de travail SOR. [Standards, Options and Recommendations for the management of ductal carcinoma in situ of the breast (DCIS): update 2004]. Bull Cancer. 2005 Feb;92(2):155-68. French.</citation>
    <PMID>15749645</PMID>
  </reference>
  <reference>
    <citation>Emdin SO, Granstrand B, Ringberg A, Sandelin K, Arnesson LG, Nordgren H, Anderson H, Garmo H, Holmberg L, Wallgren A; Swedish Breast Cancer Group. SweDCIS: Radiotherapy after sector resection for ductal carcinoma in situ of the breast. Results of a randomised trial in a population offered mammography screening. Acta Oncol. 2006;45(5):536-43.</citation>
    <PMID>16864166</PMID>
  </reference>
  <reference>
    <citation>Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996 Mar 27;275(12):913-8.</citation>
    <PMID>8598618</PMID>
  </reference>
  <reference>
    <citation>Fine JP. Regression modeling of competing crude failure probabilities. Biostatistics. 2001 Mar;2(1):85-97.</citation>
    <PMID>12933558</PMID>
  </reference>
  <reference>
    <citation>Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999 Jun 12;353(9169):1993-2000.</citation>
    <PMID>10376613</PMID>
  </reference>
  <reference>
    <citation>Fisher B, Land S, Mamounas E, Dignam J, Fisher ER, Wolmark N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol. 2001 Aug;28(4):400-18.</citation>
    <PMID>11498833</PMID>
  </reference>
  <reference>
    <citation>Gagliardi G, Lax I, Söderström S, Gyenes G, Rutqvist LE. Prediction of excess risk of long-term cardiac mortality after radiotherapy of stage I breast cancer. Radiother Oncol. 1998 Jan;46(1):63-71.</citation>
    <PMID>9488129</PMID>
  </reference>
  <reference>
    <citation>Ho AY, Atencio DP, Peters S, Stock RG, Formenti SC, Cesaretti JA, Green S, Haffty B, Drumea K, Leitzin L, Kuten A, Azria D, Ozsahin M, Overgaard J, Andreassen CN, Trop CS, Park J, Rosenstein BS. Genetic predictors of adverse radiotherapy effects: the Gene-PARE project. Int J Radiat Oncol Biol Phys. 2006 Jul 1;65(3):646-55.</citation>
    <PMID>16751059</PMID>
  </reference>
  <reference>
    <citation>Houghton J, George WD, Cuzick J, Duggan C, Fentiman IS, Spittle M; UK Coordinating Committee on Cancer Research; Ductal Carcinoma in situ Working Party; DCIS trialists in the UK, Australia, and New Zealand. Radiotherapy and tamoxifen in women with completely excised ductal carcinoma in situ of the breast in the UK, Australia, and New Zealand: randomised controlled trial. Lancet. 2003 Jul 12;362(9378):95-102.</citation>
    <PMID>12867108</PMID>
  </reference>
  <reference>
    <citation>Omlin A, Amichetti M, Azria D, Cole BF, Fourneret P, Poortmans P, Naehrig D, Miller RC, Krengli M, Gutierrez Miguelez C, Morgan D, Goldberg H, Scandolaro L, Gastelblum P, Ozsahin M, Dohr D, Christie D, Oppitz U, Abacioglu U, Gruber G. Boost radiotherapy in young women with ductal carcinoma in situ: a multicentre, retrospective study of the Rare Cancer Network. Lancet Oncol. 2006 Aug;7(8):652-6.</citation>
    <PMID>16887482</PMID>
  </reference>
  <reference>
    <citation>Ozsahin M, Crompton NE, Gourgou S, Kramar A, Li L, Shi Y, Sozzi WJ, Zouhair A, Mirimanoff RO, Azria D. CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients. Clin Cancer Res. 2005 Oct 15;11(20):7426-33.</citation>
    <PMID>16243816</PMID>
  </reference>
  <reference>
    <citation>Solin LJ, Fourquet A, Vicini FA, Haffty B, Taylor M, McCormick B, McNeese M, Pierce LJ, Landmann C, Olivotto IA, Borger J, Kim J, de la Rochefordiere A, Schultz DJ. Mammographically detected ductal carcinoma in situ of the breast treated with breast-conserving surgery and definitive breast irradiation: long-term outcome and prognostic significance of patient age and margin status. Int J Radiat Oncol Biol Phys. 2001 Jul 15;50(4):991-1002.</citation>
    <PMID>11429227</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 22, 2009</study_first_submitted>
  <study_first_submitted_qc>May 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2009</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ductal breast carcinoma in situ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma in Situ</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

